"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 22 | 14 | 36 |
| 1997 | 25 | 14 | 39 |
| 1998 | 36 | 12 | 48 |
| 1999 | 27 | 17 | 44 |
| 2000 | 14 | 12 | 26 |
| 2001 | 19 | 13 | 32 |
| 2002 | 8 | 5 | 13 |
| 2003 | 18 | 8 | 26 |
| 2004 | 13 | 15 | 28 |
| 2005 | 14 | 10 | 24 |
| 2006 | 18 | 12 | 30 |
| 2007 | 9 | 10 | 19 |
| 2008 | 8 | 12 | 20 |
| 2009 | 12 | 9 | 21 |
| 2010 | 13 | 14 | 27 |
| 2011 | 13 | 8 | 21 |
| 2012 | 13 | 11 | 24 |
| 2013 | 17 | 14 | 31 |
| 2014 | 19 | 11 | 30 |
| 2015 | 4 | 13 | 17 |
| 2016 | 13 | 9 | 22 |
| 2017 | 11 | 6 | 17 |
| 2018 | 8 | 8 | 16 |
| 2019 | 8 | 13 | 21 |
| 2020 | 8 | 10 | 18 |
| 2021 | 7 | 6 | 13 |
| 2022 | 1 | 8 | 9 |
| 2023 | 0 | 9 | 9 |
| 2024 | 5 | 8 | 13 |
| 2025 | 5 | 8 | 13 |
| 2026 | 5 | 4 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Mycophenolate and azathioprine in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2026 Oct 01; 212(10):2493-2503.
-
The gut microbiome and allograft outcomes: implications for heart transplantation. J Clin Invest. 2026 08 17; 136(16).
-
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus. J Crohns Colitis. 2026 May 08; 20(5).
-
The management of rheumatic immune related adverse events. Best Pract Res Clin Rheumatol. 2026 Mar; 40(1):102147.
-
Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients. JAMA Netw Open. 2026 05 01; 9(5):e2614323.
-
Molecular endotypes predict differential response to immunosuppressant therapy in non-idiopathic pulmonary fibrosis interstitial lung disease. Am J Respir Crit Care Med. 2026 Apr 01; 212(4):768-777.
-
A Rare Case of Seronegative anti-Glomerular Basement Membrane Disease with Pulmonary Involvement. R I Med J (2013). 2026 Apr 01; 109(4):52-54.
-
A systematic review of post-liver transplantation treatment and outcomes for late T-cell mediated, chronic ductopenic, and antibody-mediated rejection. Hepatol Commun. 2026 Mar 01; 10(3).
-
Association between genetically predicted expression of TPMT and azathioprine adverse events. BMC Pharmacol Toxicol. 2026 Feb 07; 27(1).
-
Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines Into Clinical Practice. Chest. 2026 Oct; 170(4):1138-1151.